Table 1. Clinicopathologic characteristics of 116 EOC patients.
| Characteristics | No. of patients (%) | Chemoresistance | |
|---|---|---|---|
| No n = 86 (%) | Yes n = 30 (%) | ||
| Age | |||
| < 50 | 43 (37.1) | 29 (33.7) | 14 (46.7) |
| ≥ 50 | 73 (62.9) | 57 (66.3) | 16 (53.3) |
| Ascites | |||
| < 100 | 41 (35.3) | 35 (40.7) | 6 (20.0) |
| ≥ 100 | 75 (64.7) | 51 (59.3) | 24 (80.0) |
| Serum CA-125 level | |||
| < 35 | 8 (7.0) | 6 (7.0) | 2 (6.7) |
| ≥ 35 | 108 (93.0) | 80 (93.0) | 28 (93.3) |
| Lymph node metastasis | |||
| Negative | 71 (61.2) | 71 (82.6) | 0 (0.0) |
| Positive | 45 (38.8) | 15 (17.4) | 30 (100.0) |
| Tumor differentiation | |||
| G1 | 23 (19.8) | 20 (23.3) | 3 (10.0) |
| G2 | 41 (35.3) | 34 (39.5) | 7 (23.3) |
| G3 | 52 (44.8) | 32 (37.2) | 20 (66.7) |
| Histology type | |||
| Serous | 82 (70.7) | 64 (74.3) | 18 (70.7) |
| Mucinous | 14 (12.1) | 12 (14.0) | 2 (12.1) |
| Endometrioid | 16 (13.8) | 9 (10.5) | 7 (13.8) |
| Clear cell | 4 (3.4) | 1 (1.2) | 3 (3.4) |
| Residual tumor size | |||
| < 1 cm | 80 (69.0) | 67 (77.9) | 13 (43.3) |
| ≥ 1 cm | 36 (31.0) | 19 (22.1) | 17 (56.7) |
| FIGO stage | |||
| I–II | 15 (12.9) | 1 (15.1) | 2 (6.7) |
| III–IV | 101 (87.1) | 73 (84.9) | 28 (93.3) |
| Chemotherapy plan | |||
| TP | 73 (62.9) | 51 (59.3) | 22 (73.3) |
| PAC | 43 (37.1) | 35 (40.7) | 8 (26.7) |
| miR-520g expression | |||
| Low | 40 (34.5) | 37 (43.0) | 3 (10.0) |
| High | 76 (65.5) | 49 (57.0) | 27 (90.0) |
FIGO: International Federation of Gynecology and Obstetrics.